Bausch Health shares rise as Q2 earnings soar past estimates

Bausch Health Companies Inc. reported second-quarter results that significantly exceeded analyst expectations, with adjusted EPS of $0.40 against a $0.04 consensus and revenue of $2.53 billion beating estimates, driving shares up 2.8%. This marks the company's ninth consecutive quarter of year-over-year growth, bolstered by strong performance in segments like Salix and Solta Medical. Consequently, Bausch Health raised its full-year 2025 revenue and Adjusted EBITDA guidance, signaling an upbeat outlook.

Analysis

Bausch Health Companies Inc. (BHC) reported a robust second quarter, significantly outperforming market expectations. The company posted an adjusted EPS of $0.40, a tenfold beat against the $0.04 analyst consensus, on revenue of $2.53 billion which surpassed estimates of $2.48 billion. This performance, marking the ninth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth ex-Bausch + Lomb, was driven by notable strength in key divisions. The Salix segment grew 12% YoY to $627 million, largely due to a 10% revenue increase from its Xifaxan product, while the Solta Medical segment expanded by an impressive 25% to $128 million. Management's confidence is reflected in its raised full-year 2025 guidance, with revenue now projected at $10 to $10.25 billion and Adjusted EBITDA at $3.485 to $3.635 billion, both ahead of consensus. However, a critical counterpoint is the 24% YoY decrease in cash from operating activities to $289 million, which warrants scrutiny as it contrasts with the strong profitability metrics. The company's R&D pipeline, including the RED-C drug with Phase 3 results expected by early 2026, represents a long-term potential catalyst.

Key Decisions for Investors

• The substantial earnings beat and upgraded full-year guidance may reinforce a bullish thesis for investors, as operational momentum in the Salix and Solta segments appears strong.
• Investors should closely scrutinize the company's cash flow statements in coming quarters, as the 24% year-over-year decline in operating cash flow is a significant risk factor that diverges from the positive earnings narrative.
• While the R&D pipeline offers long-term upside, key clinical data for RED-C is not expected until early 2026, suggesting that near-term valuation should be primarily based on the performance of the existing commercial portfolio.